Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient.

MLA

García-Álvarez, Rosa María, et al. “Impact of Prior Antihypertensive Treatment on COVID-19 Outcomes, by Active Ingredient.” Inflammopharmacology, vol. 32, no. 3, June 2024, pp. 1805–15. EBSCOhost, https://doi.org/10.1007/s10787-024-01475-2.

APA

García-Álvarez, R. M., Zapata-Cachafeiro, M., Visos-Varela, I., Rodríguez-Fernández, A., Pintos-Rodríguez, S., Piñeiro-Lamas, M., Herdeiro, T. M., Figueiras, A., & Salgado-Barreira, A. (2024). Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient. Inflammopharmacology, 32(3), 1805–1815. https://doi.org/10.1007/s10787-024-01475-2

Chicago

García-Álvarez, Rosa María, Maruxa Zapata-Cachafeiro, Irene Visos-Varela, Almudena Rodríguez-Fernández, Samuel Pintos-Rodríguez, Maria Piñeiro-Lamas, Teresa M Herdeiro, Adolfo Figueiras, and Angel Salgado-Barreira. 2024. “Impact of Prior Antihypertensive Treatment on COVID-19 Outcomes, by Active Ingredient.” Inflammopharmacology 32 (3): 1805–15. doi:10.1007/s10787-024-01475-2.